First, make sure the FDA stays involved

Quick Read

Dr. Scott Gottlieb isn’t rolling back his agency’s mission, although he is straddling the interests of the drug and health industries along with public health

Quick Read

Dozens of doctors, medical ethicists, and lawyers are warning Congress that legislation to allow Americans with life-threatening conditions access to unapproved, experimental drugs risks harming patients’ health

Quick Read

It’s a disaster in the making…it’s actually an approach that could do more harm than good for people who seemingly have “nothing left to lose.” I’m also not sure why such a law is needed, since people like me already have access to experimental therapies

Quick Read

Christopher Robertson and Kelly McBride Folkers write, “Despite the policy’s broad support, it has yet to help a single patient in Arizona obtain an experimental drug that they couldn’t have gotten before. Thirty-seven other states have also passed right to try bills, but likewise have seen little real impact for patients.”

Quick Read

In September, the U.S. Department of Agriculture gave the green light to a version of the plant Camelina sativa, an important oilseed crop that had been genetically engineered using CRISPR to produce enhanced omega-3 oil. What was interesting about this approval was that the USDA did not ask that the inventors of the plant endure the usual regulatory hoops required to sell biotech crops

Quick Read

On Monday, the Food and Drug Administration announced plans to crack down on so-called “homeopathic remedies”—treatments that due to agency enforcement policy have managed to avoid regulatory oversight

Quick Read

The Uncertain Hour Podcast explores food regulation and the story of Ruth Desmond AKA “Peanut Butter Grandma”. Featuring comments from our Angie Boyce.

Read More